Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample
Using US National Survey on Drug Use and Health data (2005–2018), the study found that lifetime MDMA (ecstasy) use was associated with lower risk of overweight/obesity and reduced odds of past-year heart condition/cancer, hypertension and diabetes, and with higher odds of reporting better overall health. These associations remained after adjustment for multiple confounders, though the authors note longitudinal studies and clinical trials are needed to test causality.
Authors
- Otto Simonsson
- Peter Hendricks
Published
Abstract
Introduction
3,4-Methylenedioxymethamphetamine (MDMA/“ecstasy”) is an empathogen that can give rise to increased pleasure and empathy and may effectively treat post-traumatic stress disorder. Although prior research has demonstrated associations between ecstasy use and favorable mental health outcomes, the associations between ecstasy and physical health have largely been unexplored. Thus, the goal of this study was to examine the associations between ecstasy use and physical health in a population-based survey sample.
Method
This study utilized data from the National Survey on Drug Use and Health (2005–2018), a yearly survey that collects information on substance use and health outcomes in a nationally representative sample of U.S. adults. We used multinomial, ordered, and logistic regression models to test the associations between lifetime ecstasy use and various markers of physical health (self-reported body mass index, overall health, past year heart condition and/or cancer, past year heart disease, past year hypertension, and past year diabetes), controlling for a range of potential confounders.
Results
Lifetime ecstasy use was associated with significantly lower risk of self-reported overweightness and obesity (adjusted relative risk ratio range: 0.55–0.88) and lower odds of self-reported past year heart condition and/or cancer (adjusted odds ratio (aOR): 0.67), hypertension (aOR: 0.85), and diabetes (aOR: 0.58). Ecstasy use was also associated with significantly higher odds of better self-reported overall health (aOR: 1.18).
Conclusion
Ecstasy shares protective associations with various physical health markers. Future longitudinal studies and clinical trials are needed to more rigorously test these associations.
Research Summary of 'Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample'
Introduction
Jones and colleagues situate the study within renewed clinical and research interest in MDMA (ecstasy), noting its empathogenic effects, acute physiological effects (for example increased heart rate and blood pressure), and recent promise as an adjunct to psychotherapy for treatment-resistant post-traumatic stress disorder. Earlier population-based work has reported protective associations between classic psychedelic use and several markers of physical health, and some observational and clinical reports suggest MDMA-assisted therapy can reduce comorbid conditions that influence physical health. Despite these threads, the authors identify a gap: few studies have examined associations between ecstasy use and broad markers of physical health in population-representative samples. This study therefore aimed to test whether lifetime ecstasy use is associated with a range of self-reported physical health markers in a nationally representative U.S. survey. Specifically, the investigators sought to replicate and extend prior findings on classic psychedelics by examining relationships between lifetime ecstasy use and body mass index (BMI), overall self-rated health, and several past-year cardiometabolic and disease outcomes.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Jones, G., Ricard, J. A., Hendricks, P., & Simonsson, O. (2022). Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample. Journal of Psychopharmacology, 36(10), 1129-1135. https://doi.org/10.1177/02698811221127318
References (27)
Papers cited by this study that are also in Blossom
Brewerton, T. D., Wang, J. B., Lafrance, A. et al. · Journal of Psychiatric Research (2022)
Danforth, A. L., Grob, C. S., Struble, C. et al. · Psychopharmacology (2018)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B. et al. · Frontiers in Psychiatry (2019)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Hendricks, P. S., Crawford, M. S., Cropsey, K. L. et al. · Journal of Psychopharmacology (2017)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Jones, G. M., Lipson, J., Nock, M. K. · Scientific Reports (2022)
Show all 27 referencesShow fewer
Jones, G. M., Nock, M. K. · Journal of Psychopharmacology (2022)
Jones, G. M., Nock, M. K. · Journal of Psychopharmacology (2022)
Jones, G. M., Nock, M. K. · Journal of Psychopharmacology (2022)
Jones, G. M., Nock, M. K. · Scientific Reports (2022)
Jones, G. M., Ricard, J. A., Lipson, J. et al. · Scientific Reports (2022)
Luoma, J. B., Lear, M. K. · Frontiers in Psychiatry (2021)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2012)
Ona, G., Kohek, M., Massaguer, T. et al. · Journal of Psychoactive Drugs (2019)
Simonsson, O., Hendricks, P. S., Carhart-Harris, R. et al. · Hypertension (2021)
Simonsson, O., Osika, W., Carhart-Harris, R. L. et al. · Scientific Reports (2021)
Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)
Szabo, A. · Frontiers in Immunology (2015)
Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)
Vegting, Y., Reneman, L., Booij, J. · Psychopharmacology (2016)
Vollenweider, F. X., Gamma, A., Liechti, M. et al. · Neuropsychopharmacology (1998)
Cited By (1)
Papers in Blossom that reference this study
Jones, G. M., Lipson, J., Wang, E. · Scientific Reports (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.